Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1161 participants.

Also called NCT01599104

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,161 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01599104
Other papers using this trial's data
  • Twenty-Four-Hour Blood Pressure-Lowering Efficacy of Sacubitril/Valsartan Versus Olmesartan in Japanese Patients With Essential Hypertension Based on Nocturnal Blood Pressure Dipping Status: A Post Hoc Analysis of Data From a Randomized, Double-Blind Multicenter Study Journal of the American Heart Association, 2023-04-18 DOI, PubMed 37026551, PMC10227270 In the PMC Open Access subset under CC BY.

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01599104. Randomized; quadruple masking; primary purpose treatment. Start 2012-06 (registry gives no type); primary completion 2013-04 (actual). Results posted on 2015-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 in Comparison to Olmesartan in Japanese Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
LCZ696
Intervention (Drug)
Olmesartan
Intervention (Drug)
Placebo
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01599104
Content hash
25ae9f8aace3621634b726f672b34abdf0e72eb5e0e5260437328db4798ab7ff